article
21 September 2015 | By Niklas Larsson (AstraZeneca), Torben Østerlund (AstraZeneca)
The large family of pharmaceutical targets represented by G-protein coupled receptors (GPCRs) are usually involved in a number of intracellular effector pathways, leading to many cellular outcomes. In recent years it has been uncovered that different ligands of a given GPCR may engage the pathways selectively, in that ligands that…